Genscript Biotech stock
Price history
+74.81% over the period1 year: from $15.88 (November 20, 2025) to $27.76 (November 20, 2026), +74.81%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $27.76 |
| October 30, 2026 | $35.02 |
| September 30, 2026 | $44.86 |
| August 31, 2026 | $33.88 |
| July 31, 2026 | $18.06 |
| June 30, 2026 | $12.23 |
| May 29, 2026 | $13.68 |
| April 30, 2026 | $13.72 |
| March 31, 2026 | $10.95 |
| February 27, 2026 | $11.94 |
| January 30, 2026 | $12.85 |
| December 31, 2025 | $12.39 |
| November 28, 2025 | $14.91 |
| November 20, 2025 | $15.88 |
At a glance
The company
Manufacture and sale of life science research products and services, biologics development services, and industrial synthetic biology products
Latest results
Quarter to June 30, 2026 · EPS -$0.06
Next event
TickerLandia's take on Genscript Biotech
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−43.87% from the 52-week high
Analysts · 7 analysts
Average target$45.43+63.64% vs. price
Buy 7 · Hold 0 · Sell 0
TickerLandia Fingerprint: Genscript Biotech
Compared with similar companies: very strong momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh72
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 340.0 99 Price/book 2.16 11 Price/sales 81.4 92 Forward P/E 76.9 88 Profitabilitylow26
How much it earns on revenue and capital.
Metric Value Position in group ROA 1.5% 35 Net margin −75.4% 7 ROE −15.3% 19 Gross margin 52.0% 27 Operating margin 14.9% 43 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 47.4% 44 Loss-making yearscounts in reverse: lower means more earnings stability 4 of 5 annual reports 30 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) −22.10% 13 Earnings growth (year over year) +174.43% 90 Average revenue growth (3 years) +15.32% 41 Financial strengthlow39
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.53 9 Interest coverage 14.8 55 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.02 38 Debt/equitycounts in reverse: lower means more financial strength 0.09 56 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong83
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +74.81% 94 Relative strength (3 months) −4.58% 38 Relative strength (6 months) +142.73% 100 Distance from 200-day average +32.29% 98 Riskhigh79
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 43.5% 65 Beta (1 year) 1.17 72 Volatility (60 days) 106.2% 99
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Genscript Biotech is pricier than similar companies
Genscript Biotech's Forward P/E: 76.9, +142% against the median of a group of 10 similar companies (31.7).
Compared with 10 similar companies
| Metric | Genscript Biotech | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 76.9 | High | |
| Operating margin | 14.9% | Middle | |
| ROE | -15.3% | Low | |
| Debt/equity | 0.09 | Middle | |
| Price/book | 2.16 | Low |
Grey band: the middle half of the group; tick: the median; dot: Genscript Biotech. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$404.22M
Latest quarter · Q2 2026
Net income
-$129.34M
Latest quarter · Q2 2026
Quarterly net margin
-32.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $68.78B
- EPS
- -$2.29
- Volume
- 20.25M
- Daily trading
- €160.12M
How Genscript Biotech is changing
All resultsRevenue grew 19.7% a year on average over the last 5 years
Operating margin rose from −70.0% to 26.6%
Less cash than profit: free cash flow equal to -18% of net income
Returns
Genscript Biotech returns with dividends
$1,000 invested in Genscript Biotech 5 years ago, on November 22, 2021, would be worth $747 today with dividends reinvested: −25.28% in total, −5.67% per year. On price alone it would be $747 (−25.28%).
| Period | Genscript Biotech | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −16.94% | −6.10% | $831 |
| 6 months | +112.07% | −12.63% | $2,121 |
| Year to date | +124.05% | −12.56% | $2,241 |
| 1 year | +74.81% | −13.26% | $1,748 |
| 3 years | +16.39% | +26.06% | $1,164 |
| 5 years | −25.28% | −10.18% | $747 |
| 10 years | +631.16% | +0.24% | $7,312 |
Over the last 6 months it has done better than 100% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment
The chart in detail
Genscript Biotech: technical analysis
Genscript Biotech shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 43.5% below its all-time closing high ($49.14, October 6, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 39
- Between 30 and 70
- vs 200-session average
- +32.29%
Active signals
Close below the low of the previous 55 sessions.
The last session opened more than 3% below the previous close.
Support and resistance
Price areas where Genscript Biotech has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$28.49+2.63%2 touches, last on November 6, 2026
- Last price$27.76
- Support$15.15−45.44%6 touches, last on June 3, 2026
- Support$11.82−57.41%11 touches, last on June 22, 2026
Volatility and risk
Over the last year it has moved roughly in line with the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.17
- Volatility (60 sessions, annualised)
- 106.2%
- Largest fall in the last year
- −43.51%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Genscript Biotech: seasonality
Average monthly price change over 11 years
Over the last 11 years, the strongest month for Genscript Biotech has been August: +17.16% on average, positive in 5 years out of 11. The weakest has been March: −6.06% on average, positive in 5 years out of 11. November, the current month, has been positive in 6 years out of 10 (+4.51% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.05% | +3.71% | 7 of 11 |
| February | +7.57% | +16.00% | 6 of 11 |
| March | −6.06% | −2.83% | 5 of 11 |
| April | +5.79% | +6.18% | 6 of 11 |
| May | +6.17% | −0.29% | 5 of 11 |
| June | +3.04% | +1.62% | 6 of 11 |
| July | +11.22% | +5.04% | 7 of 11 |
| August | +17.16% | −4.98% | 5 of 11 |
| September | −3.59% | −2.79% | 5 of 11 |
| October | +6.73% | +9.93% | 6 of 11 |
| November | +4.51% | +2.02% | 6 of 10 |
| December | +4.17% | −8.10% | 3 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Genscript Biotech and its competitors
Operating with 6,135 employees, Genscript Biotech Corporation works in three areas: life science research products and services, biologics development and industrial synthetic biology. Its research range includes SurePAGE precast gels, CytoSinct cell isolation products, eZwest Lite western blotting devices and GenBox electrophoresis tanks, used in life-science research. The biologics unit helps biopharmaceutical and biotech companies develop therapeutic antibodies and gene and cell therapy products, while the industrial unit makes enzymes through non-pathogenic microbial strains.
- Headquarters
- Wan Chai, Hong Kong
- Employees
- 6,135
- Founded
- 2002
- Chief executive
- Weihui Shao
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Genscript Biotech1548 | $8.77B | 14.9% | — | +112.07% |
| Haisco Pharmaceutical Group002653 | $8.97B | 21.1% | 44.1 | +0.54% |
| ALTEOGEN196170 | $9.05B | 47.2% | 97.1 | −36.93% |
| Pharmaron Beijing300759 | $10.59B | 14.0% | 39.3 | +44.36% |
| Akeso9926 | $6.81B | -30.7% | — | −50.70% |
| Sino Biopharmaceutical1177 | $11.65B | 28.2% | 34.2 | −1.26% |
Same industry or related industries, similar size. Compare Genscript Biotech with its competitors · Full profile
